

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)
[Back](#)

[About Our Mission, Vision & Treatment](#)
[Learn About Cancer & Treatment](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA



Lab Phone

646-888-4070

Email

stadlerz@mskcc.org

Our research focuses on the identification of novel cancer-susceptibility genes using genomic technologies. We are specifically interested in helping to determine the genetic basis of “sporadic” cancers in young adults and children. By comparing germline genomes of cancer case-parent trios, the identification of de novo germline mutations is possible; such mutations appear to account for cancer susceptibility in some cancer-affected young adults and children. We are also using next-generation sequencing technologies for detection of novel cancer susceptibility loci in individuals with a familial predisposition to cancer. Ultimately, the goal of our translational research is to better understand the genetic basis of cancers, which could lead to improvements in cancer risk stratification and prevention. Our current work is supported by the Damon Runyon Cancer Research Foundation, an R21 grant from the National Cancer Institute, the Starr Cancer Consortium, and Cycle for Survival.

My Videos

- [The Inaugural BRCA 2021: Patient Symposium on Hereditary Breast and Ovarian Cancer](#)

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Zsofia K. Stadler discloses the following relationships and financial interests:

- American Society of Clinical Oncology (ASCO)
Professional Services and Activities
- SOPHiA GENETICS S.A.
Intellectual Property Rights

- UptoDate
Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#) . For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

